The Role of AI in the Management of Movement Disorders

Artificial intelligence (AI) has emerged as a transformative force in the management of movement disorders. This review explores the various applications of AI across the spectrum of care, from diagnosis to clinical workflows, treatment, and monitoring. Recent advancements include deep phenotyping tools like the Next Move in Movement Disorders (NEMO) project for hyperkinetic disorders, diagnostic platforms such as DystoniaNet, and biomarker identification systems for early Parkinson's disease detection. AI may revolutionize treatment selection through technologies like DystoniaBoTXNet and adaptive deep brain stimulation systems. For symptom monitoring, innovations like the Emerald device and smartphone-based assessment tools enable continuous, objective evaluation. AI may also enhance patient care through improved telemedicine capabilities and ambient listening. Despite these promising developments, recent critiques highlight methodological concerns in AI research, emphasizing the need for rigorous validation and transparency. The future of AI in movement disorders requires balancing technological innovation with clinical expertise to improve patient outcomes.

Authors

Institutions

Publication Details

Journal
Seminars in Neurology
Published
2025-04-29
DOI
https://doi.org/10.1055/a-2596-5950
Citations
2
Primary Topic
EEG and Brain-Computer Interfaces
Type
article
Field-Weighted Citation Impact
2.86
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Role of AI in the Management of Movement Disorders

Andres Deik
2 citations
Seminars in Neurology
EEG and Brain-Computer Interfaces
2.86
article

The Role of AI in the Management of Movement Disorders

Andres Deik
article en
2 citations

Abstract

Artificial intelligence (AI) has emerged as a transformative force in the management of movement disorders. This review explores the various applications of AI across the spectrum of care, from diagnosis to clinical workflows, treatment, and monitoring. Recent advancements include deep phenotyping tools like the Next Move in Movement Disorders (NEMO) project for hyperkinetic disorders, diagnostic platforms such as DystoniaNet, and biomarker identification systems for early Parkinson's disease detection. AI may revolutionize treatment selection through technologies like DystoniaBoTXNet and adaptive deep brain stimulation systems. For symptom monitoring, innovations like the Emerald device and smartphone-based assessment tools enable continuous, objective evaluation. AI may also enhance patient care through improved telemedicine capabilities and ambient listening. Despite these promising developments, recent critiques highlight methodological concerns in AI research, emphasizing the need for rigorous validation and transparency. The future of AI in movement disorders requires balancing technological innovation with clinical expertise to improve patient outcomes.

Seminars in NeurologyVol. 46(01)
Centre for Movement Disorders (CA), University of Pennsylvania (US)
Openalex Percentile: Top 10%
EEG and Brain-Computer Interfaces
2.86
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.